In an interim evaluation of a Phase 2 trial.

Argos’ Arcelis immunotherapy reduces viral load in interim analysis of Stage 2 HIV trial Argos Therapeutics today announced that, in an interim evaluation of a Phase 2 trial, its Arcelis immunotherapy directed at HIV, AGS-004, demonstrated a substantial reduction in viral load and a delay in viral rebound kinetics during a 12-week antiretroviral treatment interruption when compared to pre-ART viral loads. The info shall be presented in an oral poster display session. ART represents a major breakthrough for the management of HIV-infected individuals, but is not without unwanted effects and is a life-long commitment read more . Therapeutic immunotherapies to enhance immune control and response viral replication are needed to limit exposure to ART.

Importantly, both endemic nephropathy and UUC exhibited a strong family association in the endemic inhabitants. Aristolochic acid is definitely known to have toxic properties, yet certain herbal remedies have included formulations made up of Aristolochia species. This example, Dr. Grollman emphasizes, should send a red flag to public wellness officials worldwide. Supporting this warning is the U.S. Department of Health and Human Providers National Toxicology Program’s October 2011 Record on Carcinogens , which classified aristolochic acids as human being carcinogens formally.. Aristolochic acid leads to kidney failure, higher urinary tract cancer Aristolochic acid, a component of a plant found in herbal treatments since ancient times but still used in certain herbal medicines world-wide, leads to kidney failure and upper urinary system cancer in individuals exposed to the toxin.

Other Posts From Category "rheumatology":

Related Posts